Skip to main content

Dr. Hubert J. Ford III, M.D.

Pulmonology (Pulmonary Disease Physician)

  • Medicare participating

At a glance

Years since graduation
24
In the NPI registry since
2006
Medicare patients seen, 2024
176

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2002Medical school: University of Miami, Lm Miller School of Medicine
  • 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Pulmonary Disease Physician primary
    NC license 2004-01391
  • Critical Care Medicine (Internal Medicine) Physician
    NC license 2004-01391
  • Internal Medicine Physician
    NC license 2004-01391

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Pulmonology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
176
Services billed
559
Patients’ average age
72
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 30-39 minutes14188
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes3215
Established patient office or other outpatient visit, 40-54 minutes2522
Test to examine how well the lungs exchange gases1414
New patient office or other outpatient visit, 60-74 minutes1212

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Most prescribed drugs, Medicare Part D 2024
DrugPrescriptions
Tadalafil172
Opsumit (macitentan)159
Sildenafil Citrate
Other prescribers in Chapel Hill, NC
126
Trelegy Ellipta (fluticasone/umeclidin/vilanter)
Other prescribers in Chapel Hill, NC
109
Furosemide
Other prescribers in Chapel Hill, NC
102
Ambrisentan100
Breztri Aerosphere (budesonide/glycopyr/formoterol)
Other prescribers in Chapel Hill, NC
86
Adcirca (tadalafil)82
Orenitram Er (treprostinil diolamine)81
Adempas (riociguat)63

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 6 companies reported 37 payments worth $24,192 in total to this clinician.

By type
Consulting Fee$18,640
Travel and Lodging$4,722
Food and Beverage$830

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Aug 8, 2025United Therapeutics Corporation
Aug 8, 2025
Consulting Fee
REMODULIN · Pulmonary Arterial Hypertension
$8,200
Apr 14, 2025Merck Sharp & Dohme LLC
Apr 14, 2025
Consulting Fee$5,760
Oct 27, 2025Merck Sharp & Dohme LLC
Oct 27, 2025
Consulting Fee$4,480
Apr 3, 2025Merck Sharp & Dohme LLC
Apr 3, 2025
Travel and Lodging
WINREVAIR · CARDIOVASCULAR · travel to Boston, MA · in-kind
$570
Oct 16, 2025Merck Sharp & Dohme LLC
Oct 16, 2025
Travel and Lodging
WINREVAIR · CARDIOVASCULAR · travel to Chicago, IL · in-kind
$413
Oct 16, 2025Merck Sharp & Dohme LLC
Oct 16, 2025
Travel and Lodging
WINREVAIR · CARDIOVASCULAR · travel to Chicago, IL · in-kind
$410
Apr 3, 2025Merck Sharp & Dohme LLC
Apr 3, 2025
Travel and Lodging
WINREVAIR · CARDIOVASCULAR · travel to Boston, MA · in-kind
$371
Apr 3, 2025Merck Sharp & Dohme LLC
Apr 3, 2025
Travel and Lodging
WINREVAIR · CARDIOVASCULAR · travel to Boston, MA · in-kind
$357
Aug 7, 2025United Therapeutics Corporation
Aug 7, 2025
Travel and Lodging
REMODULIN · Pulmonary Arterial Hypertension · travel to Dallas, TX · in-kind
$345
Dec 3, 2025Chiesi USA, Inc.
Dec 3, 2025
Travel and Lodging
travel to BOSTON, MA · in-kind
$337
All 21 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Dec 3, 2025Chiesi USA, Inc.
Dec 3, 2025
Travel and Lodging
travel to BOSTON, MA · in-kind
$337
Nov 12, 2025Merck Sharp & Dohme LLC
Nov 12, 2025
Travel and Lodging
travel to Chicago, IL
$45.06
Oct 27, 2025Merck Sharp & Dohme LLC
Oct 27, 2025
Consulting Fee$4,480
Oct 27, 2025Merck Sharp & Dohme LLC
Oct 27, 2025
Travel and Lodging
travel to Chicago, IL
$150
Oct 17, 2025Merck Sharp & Dohme LLC
Oct 17, 2025
Travel and Lodging
WINREVAIR · CARDIOVASCULAR · travel to Chicago, IL · in-kind
$176
Oct 16, 2025Merck Sharp & Dohme LLC
Oct 16, 2025
Travel and Lodging
WINREVAIR · CARDIOVASCULAR · travel to Chicago, IL · in-kind
$413
Oct 16, 2025Merck Sharp & Dohme LLC
Oct 16, 2025
Travel and Lodging
WINREVAIR · CARDIOVASCULAR · travel to Chicago, IL · in-kind
$410
Oct 16, 2025Merck Sharp & Dohme LLC
Oct 16, 2025
Travel and Lodging
WINREVAIR · CARDIOVASCULAR · travel to Chicago, IL · in-kind
$267
Sep 30, 2025Bayer HealthCare Pharmaceuticals Inc.
Sep 30, 2025
Consulting Fee
Adempas · Cardio-pulmonary
$200
Aug 8, 2025United Therapeutics Corporation
Aug 8, 2025
Consulting Fee
REMODULIN · Pulmonary Arterial Hypertension
$8,200
Aug 8, 2025United Therapeutics Corporation
Aug 8, 2025
Travel and Lodging
REMODULIN · Pulmonary Arterial Hypertension · travel to Dallas, TX
$230
Aug 7, 2025United Therapeutics Corporation
Aug 7, 2025
Travel and Lodging
REMODULIN · Pulmonary Arterial Hypertension · travel to Dallas, TX · in-kind
$345
Aug 7, 2025United Therapeutics Corporation
Aug 7, 2025
Travel and Lodging
REMODULIN · Pulmonary Arterial Hypertension · travel to Dallas, TX · in-kind
$322
Jun 14, 2025Pfizer Inc.
Jun 14, 2025
Travel and Lodging
travel to Prague, Czech Republic · in-kind
$203
Jun 14, 2025Pfizer Inc.
Jun 14, 2025
Travel and Lodging
travel to Prague, Czech Republic · in-kind
$203
Apr 14, 2025Merck Sharp & Dohme LLC
Apr 14, 2025
Consulting Fee$5,760
Apr 14, 2025Merck Sharp & Dohme LLC
Apr 14, 2025
Travel and Lodging
travel to Boston, MA
$150
Apr 3, 2025Merck Sharp & Dohme LLC
Apr 3, 2025
Travel and Lodging
WINREVAIR · CARDIOVASCULAR · travel to Boston, MA · in-kind
$570
Apr 3, 2025Merck Sharp & Dohme LLC
Apr 3, 2025
Travel and Lodging
WINREVAIR · CARDIOVASCULAR · travel to Boston, MA · in-kind
$371
Apr 3, 2025Merck Sharp & Dohme LLC
Apr 3, 2025
Travel and Lodging
WINREVAIR · CARDIOVASCULAR · travel to Boston, MA · in-kind
$357
Apr 3, 2025Merck Sharp & Dohme LLC
Apr 3, 2025
Travel and Lodging
WINREVAIR · CARDIOVASCULAR · travel to Boston, MA · in-kind
$173

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in North Carolina →

Industry-funded research

Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $639,726 in research payments for these studies, mostly to the institutions running them.

  • An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy for the Treatment of PAH
    Merck Sharp & Dohme LLC
  • A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension
    United Therapeutics Corporation · Active, not recruiting · NCT05203510
  • A Phase 3, Randomized Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients
    Merck Sharp & Dohme LLC
  • A phase 1 randomized doubleblind placebocontrolled study to evaluate the safety tolerability pharmacokinetics and pharmacodynamics of single escalating doses of PF07868489 in healthy adult participants and repeat do…
    Pfizer Inc.
  • Prospective Multi Center double blind randomized active controlled triple dummy parallel group sequential adaptive Phase 3 clinical study to compare the efficacy and safety of macitentan and tadalafil monotherapies wi…
    Janssen Research & Development, LLC

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Pulmonology clinicians in Chapel Hill

Sources

NPI registry (CMS NPPES, November 2026; record last updated May 19, 2011), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1154433613. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.